The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: A potential novel anti-inflammatory strategy in pulmonary hypertension

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 309, Issue 4, 2015, Pages L333-L347

  Church, Alistair C ^a   Martin, Damien H ^a   Wadsworth, Roger ^b   Bryson, Gareth ^c   Fisher, Andrew J ^d   Welsh, David J ^a   Peacock, Andrew J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

P38 MAPK; Pulmonary hypertension

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA SMOOTH MUSCLE ACTIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 14; MONOCROTALINE; PH 797804; PROSTANOID; ANTIINFLAMMATORY AGENT; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CASE REPORT; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; INFLAMMATION; LUNG BLOOD VESSEL; LUNG PARENCHYMA; MEDIATOR RELEASE; MONOCROTALINE-INDUCED PULMONARY HYPERTENSION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; PULMONARY VASCULAR REMODELING; RAT; TREATMENT RESPONSE; VASCULAR REMODELING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL HYPOXIA; CELL PROLIFERATION; DRUG EFFECTS; ENZYMOLOGY; FIBROBLAST; HYPERTENSION, PULMONARY; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY ARTERY; SECRETION (PROCESS); SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL HYPOXIA; CELL PROLIFERATION; FEMALE; FIBROBLASTS; HUMANS; HYPERTENSION, PULMONARY; IMIDAZOLES; INTERLEUKIN-6; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 14; PULMONARY ARTERY; PYRIDINES; RATS, SPRAGUE-DAWLEY; VASCULAR REMODELING;

EID: 84939430093     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00038.2015     Document Type: Article

References (21)

1. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155–168, 1998.
2. Golembeski SM, West J, Tada Y, Fagan KA. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest 128: 572S–573S, 2005.
3. Hope HR, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL, Keith RH, Li X, Mbalaviele G, Messing DM, Saabye MJ, Schindler JF, Selness SR, Stillwell LI, Webb EG, Zhang J, Monahan JB. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. J Pharmacol Exp Ther 331: 882–895, 2009.
4. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S–24S, 2004.
5. Jin N, Hatton N, Swartz DR, Xia XL, Harrington MA, Larsen SH, Rhoades RA. Hypoxia activates jun-N-terminal kinase, extracellular signal-regulated protein kinase, and p38 kinase in pulmonary arteries. Am J Respir Cell Mol Biol 23: 593–601, 2000.
6. Kuldo JM, Westra J, Asgeirsdóttir SA, Kok RJ, Oosterhuis K, Rots MG, Schouten JP, Limburg PC, Molema G. Differential effects of NF-B and p38 MAPK inhibitors and combinations thereof on TNF-ß-and IL-1-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol 289: C1229–C1239, 2005.
7. Li M, Riddle SR, Frid MG, Kasmi El KC, McKinsey TA, Sokol RJ, Strassheim D, Meyrick B, Yeager ME, Flockton AR, McKeon BA, Lemon DD, Horn TR, Anwar A, Barajas C, Stenmark KR. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol 187: 2711–2722, 2011.
8. Lu J, Shimpo H, Shimamoto A, Chong AJ, Hampton CR, Spring DJ, Yada M, Takao M, Onoda K, Yada I, Pohlman TH, Verrier ED. Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats. J Thorac Cardiovasc Surg 128: 850–859, 2004.
9. MacNee W, Allan RJ, Jones I, De Salvo MC, Tan LF. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 68: 738–745, 2013.
10. Morimoto S, Nabata T, Koh E, Shiraishi T, Fukuo K, Imanaka S, Kitano S, Miyashita Y, Ogihara T. Interleukin-6 stimulates proliferation of cultured vascular smooth muscle cells independently of interleukin-1 beta. J Cardiovasc Pharmacol 17, Suppl 2: S117–8, 1991.
11. Mortimer HJ, Peacock AJ, Kirk A, Welsh DJ. p38 MAP kinase: essential role in hypoxia-mediated human pulmonary artery fibroblast proliferation. Pulm Pharmacol Ther 20: 718–725, 2007.
12. Peacock AJ, Scott P, Plevin R, Wadsworth R, Welsh D. Hypoxia enhances proliferation and generation of IP3 in pulmonary artery fibroblasts but not in those from the mesenteric circulation. Chest 114: 24S, 1998.
13. Rose F, Grimminger F, Appel J, Heller M, Pies V, Weissmann N, Fink L, Schmidt S, Krick S, Camenisch G, Gassmann M, Seeger W, Hänze J. Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cells: role of hypoxia-inducible transcription factors. FASEB J 16: 1660–1661, 2002.
14. Scott PH, Paul A, Belham CM, Peacock AJ, Wadsworth RM, Gould GW, Welsh D, Plevin R. Hypoxic stimulation of the stress-activated protein kinases in pulmonary artery fibroblasts. Am J Respir Crit Care Med 158: 958–962, 1998.
15. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, Walker C, Budd DC, Pepke-Zaba J, Morrell NW. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122: 920–927, 2010.
16. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104: 236-44-28 p following 244, 2009.
17. Stenmark KR, Davie N, Frid M, Gerasimovskaya E, Das M. Role of the adventitia in pulmonary vascular remodeling. Physiology (Bethesda) 21: 134–145, 2006.
18. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 279: L895–L902, 2000.
19. Weerackody RP, Welsh DJ, Wadsworth RM, Peacock AJ. Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. Am J Physiol Heart Circ Physiol 296: H1312–H1320, 2009.
20. Welsh DJ, Peacock AJ, MacLean M, Harnett M. Chronic hypoxia induces constitutive p38 mitogen-activated protein kinase activity that correlates with enhanced cellular proliferation in fibroblasts from rat pulmonary but not systemic arteries. Am J Respir Crit Care Med 164: 282–289, 2001.
21. Welsh DJ, Scott PH, Peacock AJ. p38 MAP kinase isoform activity and cell cycle regulators in the proliferative response of pulmonary and systemic artery fibroblasts to acute hypoxia. Pulm Pharmacol Ther 19: 128–138, 2006.